WASHINGTON, Jan. 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VNDA) today announced that it has received a decision letter from the U.S. Food and Drug Administration's (FDA) Center for Drug ...
WASHINGTON, May 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VNDA) today announced financial and operational results for the first quarter ended March 31, 2025. "Vanda has entered a new growth ...
Vanda asked Martin Makary, the Commissioner of the Food and Drug Administration, to review the decision made by Jacqueline Corrigan-Curay, the departing director of the FDA's Center for Drug ...
The Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) issued a notice summarizing the grounds for refusing a new drug application (NDA) ...
Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA). Such investors are ...
Multiyear agreement includes exclusive Monumental Sports Network studio entitlement, activations across Capitals, Wizards, and Mystics, and deep integration via community and media platforms For ...
WASHINGTON, Jan. 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program. Gastroparesis is a serious digestive ...
The end of the trading week likely can't come fast enough for Vanda Pharmaceuticals (NASDAQ: VNDA). The commercial-stage biotech's stock took an almost 6% hit on Thursday, following some dispiriting ...
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder Provided by PR Newswire Jan 8, 2026, 4:00:00 AM Vanda Pharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results